TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02891174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with ibuprofen followed by acetaminophen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with ibuprofen followed by acetaminophen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with acetaminophen followed by ibuprofen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with acetaminophen followed by ibuprofen.
Study: NCT01682239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RVAP
Description: In this arm pacemaker leads will be placed in the RV apex.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RVSP
Description: In this arm pacemaker leads will be placed in the RV septum.
Study: NCT04124939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA 100 Units
Description: BOTOX for injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:~• Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA 100 Units
Description: BOTOX for injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:~• Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication.
Study: NCT04494841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duotherm VibraCool Back Device
Description: Low back plate belt with mechanicothermal and pressure intervention options.
Study: NCT00817297

Intervention type: DEVICE
Group type: OTHER
Intervention: noninvasive ventilator
Description: Experimental V60 Mask noninvasive Ventilator for treating patients with COPD, then Comparator Conventional Mask noninvasive Ventilator for treating patients with COPD in crossover study design

Intervention type: DEVICE
Group type: OTHER
Intervention: noninvasive ventilator
Description: Experimental V60 Mask noninvasive Ventilator for treating patients with COPD, then Comparator Conventional Mask noninvasive Ventilator for treating patients with COPD in crossover study design
Study: NCT04065048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy based diet
Description: The diet will be based on the detailed descriptions according to the American Heart Association, US Food and Drug Administration (FDA), and the Soyfoods Association of North America Website, which all promote soy products as having beneficial nutrient profiles with a daily consumption of 25 grams or more of soy protein (average serving = 6.25 grams), upper limit of 50g.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-soy based diet
Description: Diet of identical composition to the soy diet with the exception of soy.
Study: NCT03379675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 500 mg
Description: Participants will receive 500 mg dose of JNJ-53718678 oral solution once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 80 mg
Description: Participants will receive 80 mg dose of JNJ-53718678 oral solution along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
Study: NCT03868215

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-generation sequencing (NGS)
Description: NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy and before surgical resection.
Study: NCT04079361

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood samples
Description: Bood samples during prenatal and postnatal visits
Study: NCT03850379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000
Study: NCT01771107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV
Study: NCT02390245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free Eye Screenings
Description: This group will receive free eye screening and follow-up comprehensive ophthalmic exam if recommended.
Study: NCT04446416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviFUS System
Description: Open the BBB using focused ultrasound and contrast agent SonoVue®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: An anti-angiogenic agent to block tumor growth
Study: NCT04375150

Intervention type: DRUG
Intervention: Tyrosine kinase inhibitor (TKI)
Description: TKIs

Intervention type: DRUG
Intervention: Immuno-oncology (IO)
Description: IOs
Study: NCT04105036

Intervention type: OTHER
Intervention: Data Collection
Description: Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data Collection
Description: Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data Collection
Description: Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data Collection
Description: Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
Study: NCT03405883

Intervention type: OTHER
Intervention: Vaginal swab + endometrial biopsy
Description: In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.

Intervention type: OTHER
Intervention: Vaginal swab + endometrial biopsy
Description: In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.
Study: NCT03891706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tumor-specific TCR-T cells
Description: On day 0 and day 14, 0.5-5x10\^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Aldesleukin 3,000,000 IU. IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .
Study: NCT04377971

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SOC education
Description: Standard participant education from researcher

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask-tell-ask education
Description: Participant education using the ask-tell-ask method. First the researcher will ask a question about participant understanding of wound care and after hearing the participant's answer, the researcher will then proceed to tell the patient how to best take care of their wound using a standardized script. After the educational portion, the researcher will then ask the patient to repeat the information that was shared. If the participant's answer is wrong or incomplete, the researcher will then explain the instructions again to ensure that the participant understands the steps needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant satisfaction survey
Description: Participant satisfaction survey using components of the 16 item Skindex questionnaire and the 18 item version Patient Satisfaction Survey, adapted for treatment of skin cancer to characterize patient experience administered at two weeks post-operatively in person

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Participant satisfaction survey
Description: Participant satisfaction survey using components of the 16 item Skindex questionnaire and the 18 item version Patient Satisfaction Survey, adapted for treatment of skin cancer to characterize patient experience administered at two weeks post-operatively in person

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wound care adherence survey
Description: Wound care adherence survey administered at one week over the phone and at two weeks in person

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound care adherence survey
Description: Wound care adherence survey administered at one week over the phone and at two weeks in person
Study: NCT04482179

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TMS
Description: Active TMS will be delivered at 100% motor threshold

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CILT
Description: 60-90 minutes of CILT will be administered during each treatment session

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CILT
Description: 60-90 minutes of CILT will be administered during each treatment session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham TMS will be administered
Study: NCT02997631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDi Robot
Description: Distraction therapy using an interactive humanoid robot
Study: NCT01274793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride Citrate tablet
Description: Orally administered 5 mg mosapride citrate tablet s three times a day for 4 continuous weeks if no severe adverse effects were found.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-dose acupuncture
Description: In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-dose acupuncture
Description: In this group,the current was strong enough to reach the patients'tolerance threshold value.
Study: NCT02070575

Intervention type: OTHER
Intervention: blood draw
Description: Venous blood will be collected in an EDTA Vacutainer tubeup to 10 mL and will be immediately put on ice. This sample may be drawn as a stand-alone blood draw. Samples will be centrifuged at 1900g (3000-3200 RPM) for 15 Minutes and the serum aliquoted into freezer vials and stored at -80°C until analysis. In addition patients who have not received treatment for biochemical recurrence after their first draw are eligible for subsequent draws to determine the reproducibility of the test over time.
Study: NCT01968447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypocapnia
Description: Hyperventilation to the level of hypocapnia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normocapnia
Description: Normal ventilation to the level of nromocapnia
Study: NCT04193046

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample
Description: Prevalent (existing) and incident (new) participants who are found to either have PH or not by RHC will provide blood sample for the establishment of a biomarker signature of PH.
Study: NCT03547518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTNS treatment
Description: One-week induction consisting of three active PTNS treatments, each 2 hours long

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: One-week induction consisting of three active PTNS treatments, each 2 hours long
Study: NCT02390245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Description: This group will receive ophthalmic referral and a navigator for assistance in scheduling appointments; confirming appointments via phone, mail, email and/or text message; arranging transportation through Customized Community Transportation (CCT) and Philadelphia Paratransit Service; and trained medical interpreters as needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: This group will receive ophthalmic referral.
Study: NCT02179697

Intervention type: OTHER
Group type: OTHER
Intervention: Patient's Choice
Description: Patient chooses between surgery plus bracing or bracing alone. The patient will be followed according to the same schedule as Group 1.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery + Bracing vs. Bracing Alone
Description: Surgery + Bracing vs. Bracing Alone
Study: NCT04737616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: Fractional CO2 vaginal laser for genitourinary syndrome of menopause

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT
Description: Optical coherence tomography endoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT
Description: Optical coherence tomography endoscope
Study: NCT02953652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000
Description: Orally twice weekly
Study: NCT03128866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemipelvectomy
Description: Undergo hemipelvectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemipelvectomy
Description: Undergo hemipelvectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Given IV
Study: NCT04175613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast dose will be increased from 20 mg BID to 30 mg BID for those subjects that reach a weight of 50 kg or more during the study
Study: NCT04066283

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention in this study

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention in this study
Study: NCT04323956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parsaclisib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Given SC
Study: NCT04621318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: 60 mg, single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 60 mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: 60 mg, single-dose
Study: NCT02880891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prothetic procedure
Description: splinted crown
Study: NCT03273296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin (po) 500 mg x 3 per day for 3 days.
Study: NCT04323956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polatuzumab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT00981656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 60-minute intravenous (IV) infusion of 15 mg/m\^2 on days 1, 2, 3, 15, 16, 17, 29, 30, and 31 of radiation treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Continuous IV infusion of 500 mg/m\^2/24 hrs for 5 consecutive days during weeks 1 and 4 of radiation treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: IV bolus dose of 12 mg/m\^2 on day 1 of radiation treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Three-Dimensional Conformal Radiation Therapy
Description: Total dose to the gross bladder volume of 61.2 Gy as 34 daily fractions 5 days/week, for approximately 7 weeks.
Study: NCT04077801

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic test
Description: diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic test
Description: diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Postpartum pain
Description: test

Intervention type: DIAGNOSTIC_TEST
Intervention: Postpartum pain
Description: test

Intervention type: OTHER
Intervention: Visual analogue scale
Description: test TMJ /pelvic angle/lumber angle

Intervention type: OTHER
Intervention: Visual analogue scale
Description: test TMJ /pelvic angle/lumber angle
Study: NCT03273296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin (po) 125 mg x 4 per day for 3 days.
Study: NCT02616640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study: NCT04858087

Intervention type: OTHER
Intervention: Screening and treatment
Description: Students were screened by mRDTs and treated with artemether-lumefantrine if positive
Study: NCT02616640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03949569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy Dog
Description: Children will undergo a 5 minute unstructured session with either a certified therapy dog or with a dog who is trained and certified for animal-assisted interventions and/or animal-assisted activities. Children will be allowed to talk to, pet, and play with the therapy dog during the interaction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy Dog
Description: Children will undergo a 5 minute unstructured session with either a certified therapy dog or with a dog who is trained and certified for animal-assisted interventions and/or animal-assisted activities. Children will be allowed to talk to, pet, and play with the therapy dog during the interaction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stuffed Toy Dog
Description: Children will undergo a 5 minute unstructured session with a stuffed toy dog. Children will be allowed to talk to, pet, and play with the stuffed toy dog during the interaction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stuffed Toy Dog
Description: Children will undergo a 5 minute unstructured session with a stuffed toy dog. Children will be allowed to talk to, pet, and play with the stuffed toy dog during the interaction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stuffed Toy Dog
Description: Children will undergo a 5 minute unstructured session with a stuffed toy dog. Children will be allowed to talk to, pet, and play with the stuffed toy dog during the interaction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 Minute Puppy Video
Description: Children will watch a 5 minute puppy video.
Study: NCT04443413

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: X-ray Therapy
Description: Undergo x-ray therapy
Study: NCT03839524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG4050
Description: Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
Study: NCT00460226

Intervention type: DRUG
Intervention: lamotrigine
Description: lamotrigine treatment for 12weeks
Study: NCT02816944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided laser ablation for refractory neoplasms